DeepMed Research

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels

Completed

Conditions: Ischaemic Heart Disease
Unstable Angina
Myocardial Infarction
Angina
Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)

Interventions: Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

First Posted Date: 2019-09-20

Last Posted Date: 2021-11-05

Lead Sponsor: Bayer

Target Recruit Count: 99999

Registration Number: NCT04097912

Locations: 🇬🇧
Many Locations, Multiple Locations, United Kingdom

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Elimusertib (BAY1895344)
Drug: Pembrolizumab (Keytruda®)

First Posted Date: 2019-09-19

Last Posted Date: 2024-04-02

Lead Sponsor: Bayer

Target Recruit Count: 56

Registration Number: NCT04095273

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Johns Hopkins Hospital/Health System, Baltimore, Maryland, United States

and more 13 locations

Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)

Active, not recruiting

Conditions: Hemophilia A

Interventions: Drug: Damoctocog alfa pegol (Jivi, BAY94-9027)

First Posted Date: 2019-09-16

Last Posted Date: 2025-04-08

Lead Sponsor: Bayer

Target Recruit Count: 10

Registration Number: NCT04091386

Locations: 🇨🇳
Many Locations, Multiple Locations, Taiwan
🇺🇸
Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders, Orange, California, United States
🇺🇸
Tulane University, New Orleans, Louisiana, United States

Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)

Phase 4

Completed

Conditions: Hemophilia A

Interventions: Drug: Damoctocog alfa pegol (Jivi, BAY94-9027)

First Posted Date: 2019-09-11

Last Posted Date: 2023-07-27

Lead Sponsor: Bayer

Target Recruit Count: 32

Registration Number: NCT04085458

Locations: 🇪🇸
Ciutat Sanitaria i Universitaria de la Vall d'Hebron, Barcelona, Spain
🇪🇸
Hospital Universitari i Politecnic La Fe | Hematologia, Valencia, Spain
🇪🇸
Hospital Universitario "La Paz", Madrid, Spain

and more 10 locations

Effectiveness of Low Dose Aspirin in Decreasing the Chance Getting Stomach and Intestine Cancer

Completed

Conditions: Gastrointestinal Cancer

Interventions: Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

First Posted Date: 2019-09-09

Last Posted Date: 2022-04-19

Lead Sponsor: Bayer

Target Recruit Count: 99999

Registration Number: NCT04081831

Locations: 🇭🇰
University of Hong Kong, Hong Kong, Hong Kong

A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: BAY2416964

First Posted Date: 2019-08-28

Last Posted Date: 2024-03-06

Lead Sponsor: Bayer

Target Recruit Count: 78

Registration Number: NCT04069026

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Greenville Health System, Greenville, South Carolina, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

and more 14 locations

A Follow-up Physician Survey to Evaluate Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe

Completed

Conditions: Ophthalmology, Macular Degeneration

Interventions: Other: Physician questionnaire

First Posted Date: 2019-08-26

Last Posted Date: 2021-04-08

Lead Sponsor: Bayer

Target Recruit Count: 454

Registration Number: NCT04067583

Locations: 🇩🇪
Many locations, Multiple Locations, Germany

Bioequivalence Study for Acarbose/Metformin FDC

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Acarbose/Metformin FDC(BAY81-9783)
Drug: Glucobay
Drug: Glucophage

First Posted Date: 2019-08-22

Last Posted Date: 2020-04-13

Lead Sponsor: Bayer

Target Recruit Count: 24

Registration Number: NCT04065581

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China

Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus

Phase 2

Completed

Conditions: Functional Gastrointestinal Disorders

Interventions: Drug: STW5 (Iberogast®, BAY98-7411)
Drug: Placebo

First Posted Date: 2019-08-16

Last Posted Date: 2019-09-19

Lead Sponsor: Bayer

Target Recruit Count: 64

Registration Number: NCT04059900

Locations: 🇩🇪
Many locations, Multiple Locations, Germany

Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function

Completed

Conditions: Functional Gastrointestinal Disorders

First Posted Date: 2019-08-16

Last Posted Date: 2019-09-19

Lead Sponsor: Bayer

Target Recruit Count: 272

Registration Number: NCT04059783

Locations: 🇩🇪
Many locations, Multiple Locations, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy